Silaghi Alina, Achard Vincent, Paulmyer-Lacroix Odile, Scridon Traian, Tassistro Virginie, Duncea Ileana, Clément Karine, Dutour Anne, Grino Michel
INSERM U626, Aix-Marseille Université, Marseille Cedex 5, France.
Am J Physiol Endocrinol Metab. 2007 Nov;293(5):E1443-50. doi: 10.1152/ajpendo.00273.2007. Epub 2007 Sep 18.
Epicardial white adipose tissue (eWAT) is in close contact with coronary vessels and therefore could alter coronary homeostasis. Adrenomedullin (AM) is a potent vasodilatator and antioxidative peptide which has been shown to play a cytoprotective role in experimental models of acute myocardial infarction. We studied, using immunohistochemistry and qRT-PCR, the expression of AM and its receptors calcitonin receptor-like receptor (CRLR), and receptor activity-modifying protein (RAMP)2 and -3 in paired biopsies of subcutaneous WAT (sWAT) and eWAT obtained from patients with coronary artery disease (CAD) or without CAD (NCAD). In eWAT obtained from NCAD or CAD patients, immunoreactivity for AM, CRLR, and RAMP2 and -3 was detected in blood vessel walls and isolated stromal cells close to adipocytes. Some of the AM positive stromal cells colocalized CD68 immunoreactivity. eWAT from CAD patients showed increased AM immunoreactivity and AM gene expression. CRLR mRNA levels were comparable in sWAT of both groups and decreased by 40-50% in eWAT, irrespectively of the coronary status. RAMP2 mRNA concentrations did not change while RAMP3 mRNA levels increased in sWAT from CAD patients. There was a positive linear relationship between eWAT 11beta-hydroxysteroid dehydrogenase type 1 mRNA (11beta-HSD-1, the enzyme that converts inactive to active glucocorticoids) and AM mRNA. In conclusion, we demonstrate that AM and its receptors are expressed in eWAT. Our data suggest that eWAT AM, which could originate from macrophages, is related to 11beta-HSD-1 expression. AM synthesis, which is increased in eWAT during chronic CAD in humans, can play a cardioprotective role.
心外膜白色脂肪组织(eWAT)与冠状动脉密切接触,因此可能改变冠状动脉内环境稳态。肾上腺髓质素(AM)是一种强效血管舒张剂和抗氧化肽,已证实在急性心肌梗死实验模型中发挥细胞保护作用。我们采用免疫组织化学和定量逆转录聚合酶链反应(qRT-PCR)方法,研究了从冠心病(CAD)患者或无CAD(非CAD,NCAD)患者获取的皮下脂肪组织(sWAT)和eWAT配对活检样本中AM及其受体降钙素受体样受体(CRLR)、受体活性修饰蛋白(RAMP)2和RAMP3的表达情况。在从NCAD或CAD患者获取的eWAT中,在血管壁以及靠近脂肪细胞的孤立基质细胞中检测到了AM、CRLR以及RAMP2和RAMP3的免疫反应性。一些AM阳性基质细胞与CD68免疫反应性共定位。CAD患者的eWAT显示AM免疫反应性和AM基因表达增加。两组sWAT中的CRLR mRNA水平相当,而eWAT中的CRLR mRNA水平降低了40%-50%,与冠状动脉状态无关。CAD患者sWAT中RAMP2 mRNA浓度未改变,而RAMP3 mRNA水平升高。eWAT 11β-羟类固醇脱氢酶1型mRNA(11β-HSD-1,将无活性糖皮质激素转化为活性糖皮质激素的酶)与AM mRNA之间存在正线性关系。总之,我们证明AM及其受体在eWAT中表达。我们的数据表明,可能源自巨噬细胞的eWAT AM与11β-HSD-1表达有关。在人类慢性CAD期间eWAT中增加的AM合成可发挥心脏保护作用。